Caren van Roekel

296 Chapter 11 FIGURE 4. Mode of progression of the entire cohort (90 patients) (a) and specific for patients with extrahepatic disease at baseline (42 patients) (b). In chapter 5, the mode of progression at three months after treatment with 166 Ho or 90 Y-radioembolization was assessed according to RECIST 1.1. A distinction was made between progression based on growth of existing intra- or extrahepatic metastases and the development of new intra- or extrahepatic metastases. In 90 included patients, 69 (77%) had progressive disease, of which 97% had new metastases. Patients with extrahepatic disease at baseline had a worse prognosis than patients without extrahepatic disease; with an odds ratio of 7.8 for progressive disease and a median 3.5 months shorter overall survival.